Presenter's Information
Patrick W. Serruys, MD
| Country | Netherlands |
| Specialty | Interventional Cardiologist |
- DCB-ARC Consensus: Definitions and Standardized Endpoints for Drug-Coated Balloon Use
- Coronary Revascularization in 2040
- Chaos in Procedural MI Definitions in Trials Comparing PCI vs. CABG: How Do We Reconcile?
- Comparative Assessment of Aortic Regurgitation Post TAVR in (9) Commercially Available THV's
- Long-term(10-Year) Validation of the SYNTAX-II 2020 Score
- [Special Lecture] Angiography for Assessment of Regurgitation Post TAVR: The Minimalist Approach and the Return of the Jedi
- SYNTAX II: Impact of Physiology and Imaging on PCI Outcome
- Short DAPT Trials with Contemporary/Future DES: What Do We Expect?
- Ticagrelor Monotherapy in GLOBAL-LEARDERS and TWILIGHT: Interpretation and Clinical Implication
- Are Outcomes Following CABG for Left Main Disease Improving Over the Last Decade: A Propensity Matched Analysis from the EXCEL and SYNTAX Randomized Trials
- Lessons from SYNTAX II: Improving Decision Making in the SYNTAX III Trial
- The Future of Coronary Imaging and Coronary Physiology
- Can Improved Scaffold Technology Reduce Clinical Complications?: Insights and Speculation
- Is TAVR with STS from
- Gender in EXCEL
- The History of 40 Years of PTCA
- Trans-Apical Mitral Valve of Sinomed
- Pitfalls with Comparative Assessment of BRS and DES with Angio, IVUS and OCT
- SYNTAX-1, SYNTAX-II, SYNTAX-III: From Invasive to Non-Invasive Assessment of Coronary Stenosis
- Grand Vision for BRS Future: Natural History and Clinical Implication
- ABSORB in STEMI Trofi II
- Next BRS: What Are Going to Change?
- Forecasting Mortality in Left-Main Disease with the Syntax Score II Model Applied to the EXCEL Trial
- Left-Main Disease Population
- BRS Mechanical Properties: From Bench to Bedsides
- Multi Slide Findings in More Than 1000 Consecutive Patients for TAVR
- Unprotected Left Main Coronary Disease: Thoughtful Insights
- SURTAVI: Transaortic Valve Replacement Compared to Surgical Aortic Valve Replacement in Medium-Risk Patients
- Unrestricted Adoption in Real World Patients Is Possible.
- Yes, It Can Replace Metal Stent.
- Future of BRS
- Serial Follow-up Imaging of Bioresorbable Vascular Scaffolds and Clinical Implication
- Theoretical Construct: Why BRS May Change the Landscape of Coronary Intervention?
- New Metallic DES: Bioresorbable Polymers or Polymer-Free
- Comparison of Zotarolimus-Eluting and Everolimus-Eluting Coronary Stents
- Evaluation of the Second Generation of a Bioresorbable Everolimus Drug-Eluting Vascular Scaffold for Treatment of De Novo Coronary Artery Stenosis: Six-Month Clinical and Imaging Outcomes
- BIOMATRIX: Learned from the Three-Year LEADERS Trial
- Updated Guideline of LM PCI: Three-Year Follow-up of SYNTAX LM Subgroup Analysis
- Will Bioabsorbable Stents Transform PCI in the Future?
- Complications after TAVI: VARC Definitions, Frequency, and Management Considerations
- Systemic Therapy for Plaque Stabilization: New Drugs Targeting LP-PLA2
- LEADERS: Analysis of 9 Months OCT Results
- Assessment of LEADERS 12 Months Result
- Vulnerable Plaque Trials Using Surrogate Imaging Marker
- Diabetic Patients with Multivessel Disease: Stents or Surgery?
- Perspective of LM Stenting with Current Registry and Randomized Clinical Data
- Time to Move into Stenting in All Patients !
- SYNTAX: Anatomic Complexity Determines PCI Outcomes (Practical Use of the SYNTAX Score)
- SYNTAX - Data Synthesis and Clinical Recommendations
- Mortality After PCI with BMS and DES from the Thoraxcentre Database
- DELFT Registry and LM SYNTAX Update
- VH and OCT of Biodegradable Solution Stent
- Drug Eluting Stent- The Beginning of the End or the End of the Beginning
